PDUFA VII: Human Factors Review, Finance Flexibility, REMS, And Manufacturing Get Attention
Executive Summary
User fee reauthorization negotiators from US FDA and industry divide into subgroups to tackle specific issues before moving to the broader agreement.
You may also be interested in...
How The US FDA Honed Remote Tools To Assess Facilities During COVID Inspection Hiatus
FDA officials outline the impact of using alternative tools to assess manufacturing facilities amid COVID-19 and share key experiences around these, including with remote interactive evaluations.
How The US FDA Honed Remote Tools To Assess Facilities During COVID Inspection Hiatus
FDA officials outline the impact of using alternative tools to assess manufacturing facilities amid COVID-19 and share key experiences around these, including with remote interactive evaluations.
A PDUFA First: Pre-Approval Inspection Notice Goal Will Be Created
Under new user fee agreement, sponsors will get at least 60-day notice when a pre-approval inspection is necessary; regulators and manufacturers hope increased communications will lead to more efficient reviews.